



RECEIVED

JUN 13 2001

Dkt. 0179/61248-A/JPW/BJA

RECEIVED

JUN 08 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900
RECEIVED

Applicants : Gregory B. Wilson and R. Riley Shuler
U.S. Serial No. : 09/776,010
Filed : February 2, 2001
For : HUMAN HERPESVIRUS 6A AND 6B TRANSFER
FACTORS FOR THE TREATMENT OF CHRONIC
FATIGUE SYNDROME AND MULTIPLE SCLEROSIS

JUN 22 2001

TECH CENTER 1600/2900

1185 Avenue of the Americas
New York, New York 10036
June 4, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. § 1.56, applicants would like to direct the Examiner's attention to the following references which are listed on the attached Form PTO-1449 (**Exhibit 1**) and attached hereto as **Exhibits 2-7**:

1. U.S. Patent No. 4,816,563, issued March 3, 1989, Wilson et al. (**Exhibit 2**);
2. U.S. Patent No. 4,610,878, issued September 9, 1986, Wilson et al. (**Exhibit 3**);
3. Ablashi et al., Use of anti HHV-6 transfer factor for the treatment of two patients with chronic fatigue syndrome (CFS). Two case reports. *Biotherapy*, 9:81-86, 1996 (**Exhibit 4**);
4. Vinci et al., Lessons from a pilot study of transfer factor in

Gregory B. Wilson et al.
Serial No.: 09/776,010
Filed: February 2, 2001
Page 2


chronic fatigue syndrome. Biotherapy, 9:87-90, 1996 (**Exhibit 5**);

5. Kim et al., Detection of human herpesvirus 6 variant A in peripheral blood mononuclear cells for multiple sclerosis patients. *Eur. Neurol.* 43:170-173, 2000 (**Exhibit 6**); and
6. Challoner et al., Plague associated expression of human herpesvirus-6 in multiple sclerosis. *PNAS*, 92:7440-7444, 1995 (**Exhibit 7**).

If a telephone interview would be of assistance in advancing the prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided.


No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:
Assistant Commissioner for Patents,
Washington, D.C. 20231.


John P. White
Reg. No. 28,678

6/7/01

Date